deltatrials
Completed PHASE2/PHASE3 NCT00820339

Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy

Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy About Recurrence and Survival :A Prospective Randomized Trial

Sponsor: Eastern Hepatobiliary Surgery Hospital

Conditions Hepatocellular Carcinoma
Interventions Pringle's Maneuver Selective Hepatic Vascular Exclusion
Updated 5 times since 2017 Last updated: Mar 30, 2016 Started: Jan 31, 2009 Primary completion: Dec 31, 2010 Completion: Nov 30, 2012

A PHASE2/PHASE3 clinical study on Hepatocellular Carcinoma, this trial is completed. The trial is conducted by Eastern Hepatobiliary Surgery Hospital and has accumulated 5 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2_PHASE3

    First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eastern Hepatobiliary Surgery Hospital
Data source: Eastern Hepatobiliary Surgery Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Shanghai, China